The Amazing Gary Ferrar, Allergy Action Awards 2022
Thank you to those who were able the festivities and support the organization. For those that that couldn't join us, enjoy the great fun had by all with the magician and mentalist Gary Ferrar. Gary amazed us all with feats of magic and "how did he do that?" We also learned our new favorite word is "labadalabada." Watch to the end to see why.
Articles for Advocacy
In an anaphylaxis emergency, epinephrine is THE physician recommended first line medication! No other treatment counteracts all the dangerous symptoms of anaphylaxis as quickly and effectively as epinephrine. But because epinephrine is administered with an auto injector (EAI) device which has a needle and requires an intermuscular injection, some doctors are reluctant to prescribe the device. Patients are also needlessly afraid to use one. Schools and other entities who are permitted to stock epinephrine are afraid to do so. It's a paradox that could cost someone's life. Our Epi Near You New York program addresses the issue of fear of epinephrine. Read more about how we can educate doctors to prescribe epinephrine sooner in the diagnostic process.
Epinephrine Autoinjectors Not Prescribed to Half of Adults With Severe Food Allergy
By Brandon May
November 11, 2022
LOUISVILLE, Kentucky — Nearly half of adults with food allergies have not been prescribed an epinephrine autoinjector (EAI) by their physician, according to survey results presented here at the American College of Allergy, Asthma, and Immunology (ACAAI) 2022 Annual Meeting.
Research into ways to administer epinephrine without a needle has been under way for years. While the wait continues, it is exciting that neffy® the intranasal emergency epinephrine device being developed by ARS Pharmaceuticals has made it to the US FDA for review. Find the details about timing here.
FDA Accepts New Drug Application for Nasal Epinephrine Spray Treatment for Anaphylaxis
By Dave Bloom
ARS Pharmaceuticals announced today that the US Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for their neffy® nasal epinephrine device for the emergency treatment of anaphylaxis in adults and children weighing 66 lbs and more.
Clinical trials confirmed a 2mg dose of epinephrine administered intranasally provided comparable pharmacokinetics as an administration from a traditional auto-injector.